Innovation Incentives and Biomarkers. Issue 1 (16th October 2017)

• Record Type: Journal Article
• Authors: Stern, Ariel D.; Alexander, Brian M.; Chandra, Amitabh
• Is Part Of: Clinical pharmacology & therapeutics. Volume 103:Issue 1(2018)
• Page Start: 34
• Page End: 36
• Publication Date: 2017-10-16
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.876
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Previously, we have discussed the importance of economic incentives in shaping markets for precision medicines.1 Here we consider incentives for biomarker development, including discovery and establishment. Biomarkers can reveal valuable information regarding diagnosis and prognosis, predict treatment efficacy or toxicity, serve as markers of disease progression, and serve as auxiliary endpoints for clinical trials. Some have multiple uses, while others have a specialized role, resulting in diverse incentives across players in the healthcare system.